CALGARY, AB--(Marketwired - May 11, 2015) - Hemostemix Inc. (the "Corporation") (TSX VENTURE: HEM), a clinical-stage autologous cell-therapy company, announced today that it has retained Stonegate Capital Partners, Inc. ("Stonegate") to assist with strategic investor relations services in the U.S. institutional investment community. Stonegate provides a full range of services to help a select group of public company clients build awareness, manage investor expectations, and broaden and strengthen investor relationships with a strong focus on institutional investors.
"We are committed to expanding our investor relations efforts, and we have a compelling story to tell," said Dr. Elmar Burchardt, president and CEO of Hemostemix. "Stonegate's extensive institutional relationships and experience with complex capital market issues will help us communicate with current shareholders and prospective investors as we create long-term shareholder value."
About Stonegate Capital Partners
Stonegate Capital Partners is a privately owned investment banking and corporate advisory firm that is based in Dallas, Texas, and dedicated to serving the specialized needs of public companies. For over 40 years, Stonegate has been bringing public companies and institutional investors together, either by virtue of private placements, coordinating block trades, or through open market transactions.
Since inception, Stonegate's mission has been to find innovative, undervalued public companies for its network of leading institutional investors who seek high quality investment opportunities. Its robust institutional outreach effort is the foundation of the firm, and a core aspect of its success. This, combined with their team's extensive institutional relationships and experience with complex capital market issues, creates an unparalleled platform for companies looking to grow their institutional shareholder base and ultimately realize optimal valuation in their stock. For further information, visit stonegateinc.com.
About Hemostemix
Hemostemix is a public clinical-stage biotechnology company that develops and commercializes innovative blood-derived cell therapies for medical conditions not adequately addressed by current treatments. It is the first clinical-stage biotech company to test a potential breakthrough stem-cell therapy in an international, multicenter, phase-2 clinical trial for patients with critical limb ischemia (CLI), a severe form of peripheral artery disease (PAD) caused by reduced blood flow to the legs. The phase-2 trial targets a participant's diseased tissue with proprietary cells that are grown from his or her blood and capable of supporting the formation of new blood vessels. Hemostemix currently enrolls participants in the phase-2 trial at four sites in South Africa and two sites in Canada.
Hemostemix Inc. is traded on the TSX Venture Exchange under the trading symbol HEM. For more information, visit hemostemix.com or email office@hemostemix.com.
Neither the TSX Venture Exchange, Inc. nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential," and similar expressions, or that events or conditions "will," "would," "may," "could," or "should" occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Hemostemix management on the date such statements were made. Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
